Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 13/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587503 | 1.00 | PLG (0.42) | PLGGABRA1GABRG2GABRB3HCRTR2 | |
| SCHEMBL586539 | 0.87 | PLG (0.48) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL582261 | 0.87 | PLG (0.48) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL580966 | 0.87 | PLG (0.48) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL3083145 | 0.87 | PLG (0.48) | PLGGABRA1GABRG2GABRB3 | |
| SCHEMBL3076220 | 0.82 | PLG (0.43) | PLGGABRA1GABRG2GABRB3HCRTR2 | |
| SCHEMBL581435 | 0.82 | PLG (0.43) | PLGGABRA1GABRG2GABRB3HCRTR2 | |
| SCHEMBL3069006 | 0.82 | PLG (0.43) | PLGGABRA1GABRG2GABRB3HCRTR2 | |
| SCHEMBL3069017 | 0.82 | PLG (0.43) | PLGGABRA1GABRG2GABRB3HCRTR2 | |
| SCHEMBL581825 | 0.82 | PLG (0.43) | PLGGABRA1GABRG2GABRB3HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |